The biopharma industry stands at a transformative juncture as it reflects on the achievements of the past year and anticipates the evolving client requirements that will shape 2025 and beyond. Key insights from Subodh Deshmukh, CEO of Aragen Bioscience, highlight the crucial areas of focus for
January 28, 2025
In a remarkable advancement for the field of biotechnology, McMaster University and Sartorius have inaugurated a state-of-the-art bioprocessing automation laboratory at the university’s Faculty of Engineering, setting a new standard for bioprocess modeling, simulation, and advanced control. This c
January 24, 2025
The US Food and Drug Administration (FDA) raised serious concerns about Sanofi's manufacturing facility in Framingham, Massachusetts, by issuing a Warning Letter for significant deviations from current Good Manufacturing Practice (cGMP) standards for drug substance production. This alarming
January 23, 2025
In an optimistic outlook at the 43rd JPM Conference in San Francisco, Thermo Fisher CEO Marc Casper underscored the firm's strategic adaptations and growth initiatives tailored to meet surging demand for GLP-1 diabetes and weight loss products. Thermo Fisher Scientific's extensive
January 21, 2025
The contract development and manufacturing organization (CDMO) industry has seen significant advancements and partnerships as of January 2025. With a focus on large molecules and advanced therapies, this article delves into the latest developments, highlighting key trends, common themes, and
January 13, 2025
The Blood and Cell Advocacy Register (BCAR) is a newly launched consortium that aims to revolutionize the development and commercialization of advanced therapy medicinal products (ATMPs). Formed in December 2024, BCAR brings together experts and organizations from the blood and cell industries to
January 10, 2025
